GNPX Stock Price, Genprex Inc Quote, Chart

Market Summary

USD2.55+0.13

Delayed

5.37%

GNPX Stock Price

View Fullscreen

GNPX RSI Chart

GNPX Valuation

Market Cap

5.4M

Price/Earnings (Trailing)

-0.19

Price/Free Cashflow

-0.23

GNPX Price/Sales (Trailing)

GNPX Profitability

Return on Equity

-315.49%

Return on Assets

-219.88%

Free Cashflow Yield

-431.72%

GNPX Fundamentals

GNPX Earnings

Earnings (TTM)

-27.6M

Earnings Growth (Yr)

35.14%

Earnings Growth (Qtr)

-0.67%

Breaking Down GNPX Revenue

Last 7 days

9.9%

Last 30 days

15.4%

Last 90 days

-42.0%

Trailing 12 Months

-91.6%

How does GNPX drawdown profile look like?

GNPX Financial Health

Current Ratio

2.42

GNPX Investor Care

Buy Backs (1Y)

95.96%

Tracking the Latest Insider Buys and Sells of Genprex Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 18, 2024	varner john rodney	sold (taxes)	-11,624	4.4	-2,642	chairman, president and ceo
Feb 18, 2024	confer ryan m.	sold (taxes)	-4,954	4.4	-1,126	chief financial officer
Feb 18, 2024	berger mark stanley	sold (taxes)	-5,803	4.4	-1,319	chief medical officer
Jun 27, 2023	wilson william r jr.	acquired	-	-	123,795	-
Jun 27, 2023	moreno toscano jose antonio	acquired	-	-	123,795	-
Jun 27, 2023	longnecker brent m	acquired	-	-	123,795	-
Apr 21, 2023	varner john rodney	bought	20,045	1.055	19,000	chairman, president and ceo
Apr 21, 2023	vaczy catherine m	bought	21,478	1.0739	20,000	evp gc chief strategy officer
Feb 18, 2023	varner john rodney	acquired	-	-	625,000	president & ceo
Feb 18, 2023	kumar hermant	acquired	-	-	200,000	chief mfgr & tech officer

Which funds bought or sold GNPX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-4,802	-	-%
May 15, 2024	SILVERCREST ASSET MANAGEMENT GROUP LLC	sold off	-100	-12,880	-	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-1,000	-	-%
May 15, 2024	Royal Bank of Canada	new	-	-	-	-%
May 15, 2024	STATE STREET CORP	sold off	-100	-39,661	-	-%
May 15, 2024	MORGAN STANLEY	sold off	-100	-13,675	-	-%
May 15, 2024	MORGAN STANLEY	new	-	4,455	4,455	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-46.00	-	-%
May 15, 2024	Nemes Rush Group LLC	new	-	745	745	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-6,492	-	-%

Are Funds Buying or Selling GNPX?

Are funds buying GNPX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GNPX

No. of Funds

Unveiling Genprex Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	cvi investments, inc.	4.9%	3,089,092	SC 13G/A
Jul 24, 2023	cvi investments, inc.	5.8%	3,465,347	SC 13G
Feb 19, 2021	altium capital management lp	5.1%	2,400,000	SC 13G/A
Feb 16, 2021	cvi investments, inc.	-	0	SC 13G/A
Feb 16, 2021	altium capital management lp	3.3%	1,409,785	SC 13G/A
Feb 09, 2021	hudson bay capital management lp	0%	0	SC 13G/A
Jan 04, 2021	sabby management, llc	12.%	0	SC 13G/A
Dec 28, 2020	altium capital management lp	7.2%	3,116,884	SC 13G
Feb 19, 2020	roth jack a	6.0%	1,155,128	SC 13G/A
Feb 14, 2020	ly viet-an hoan	5.7%	1,169,845	SC 13G/A

Recent SEC filings of Genprex Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 29, 2024	DEFA14A	DEFA14A
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	ARS	ARS
Apr 17, 2024	S-8	Employee Benefits Plan
Apr 01, 2024	10-K	Annual Report
Mar 20, 2024	8-K	Current Report
Mar 20, 2024	424B5	Prospectus Filed
Mar 06, 2024	8-K	Current Report

Peers (Alternatives to Genprex Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Genprex Inc News

Latest updates

Genprex Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	17.7%	13.00	11.00	17.00	16.00	23.00	25.00	30.00	35.00	39.00	43.00	46.00	49.00	51.00	31.00	23.00	25.00	25.00	4.00	4.00	6.00	7.00
Current Assets	22.5%	9.00	8.00	13.00	12.00	20.00	21.00	26.00	31.00	36.00	39.00	46.00	48.00	50.00	28.00	23.00	24.00	24.00	3.00	4.00	6.00	7.00
Cash Equivalents	22.0%	8.00	7.00	12.00	10.00	18.00	21.00	26.00	30.00	35.00	39.00	42.00	44.00	47.00	27.00	21.00	22.00	23.00	2.00	3.00	4.00	7.00
Net PPE	-48.8%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-	-	-	-	-	-	-	2.00	2.00	2.00	2.00	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	17.0%	4.00	3.00	4.00	4.00	5.00	3.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	0.00
Shareholder's Equity	18.1%	9.00	7.00	12.00	12.00	18.00	22.00	27.00	32.00	37.00	41.00	45.00	48.00	50.00	31.00	23.00	25.00	24.00	3.00	4.00	5.00	7.00
Retained Earnings	-4.5%	-139	-133	-127	-120	-112	-102	-96.30	-90.16	-84.40	-79.09	-72.34	-68.90	-64.91	-58.42	-53.19	-50.42	-46.05	-40.48	-38.05	-35.68	-31.98
Additional Paid-In Capital	5.2%	148	141	140	132	130	125	124	123	121	120	117	117	115	89.00	76.00	75.00	70.00	43.00	42.00	41.00	39.00
Shares Outstanding	-	2.00	-	59.00	52.00	52.00	-	48.00	48.00	48.00	48.00	47.00	46.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	49.00	-	-	-	66.00	-	-	-	151	-	-	-	114	-	-	-	30.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-6.7%	-5,297	-4,963	-4,735	-8,107	-6,932	-4,546	-4,522	-4,480	-4,071	-3,218	-2,634	-2,966	-5,465	-3,892	-2,015	-3,510	-4,517	-1,721	-1,989	-1,565	-1,641
Share Based Compensation	-50.4%	516	1,040	1,490	1,546	1,332	1,305	1,218	1,151	1,057	2,863	675	1,137	672	674	448	2,371	754	650	582	1,775	523
Cashflow From Investing	-60.9%	-15.82	-9.83	-21.76	-20.00	-19.63	-20.00	-16.05	-21.85	-1.84	-173	168	32.00	-110	-2,341	153	-11.29	-137	-91.77	42.00	-883	-13.33
Cashflow From Financing	67931890.0%	6,793	10*	6,513	-	4,081	5.00	2.00	-	-	-	244	110	25,324	12,495	794	2,569	25,732	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GNPX Income Statement

2024-03-31

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Depreciation	$ 2,670	$ 4,016
Research and development	3,274,380	5,310,148
General and administrative	2,719,667	3,950,390
Total operating expenses	5,996,717	9,264,554
Operating loss	(5,996,717)	(9,264,554)
Interest income	27,713	68,471
Realized gain (loss)	135	(6,691)
Net loss	$ (5,968,869)	$ (9,202,774)
Net loss per share—basic and diluted (in dollars per share)	$ (3.69)	$ (7.44)
Weighted average number of common shares—basic and diluted (in shares)	1,618,240	1,236,822

GNPX Balance Sheet

2024-03-31

Condensed Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 8,217,115	$ 6,737,629
Prepaid expenses and other	1,010,761	794,138
Total current assets	9,227,876	7,531,767
Property and equipment, net	4,023	7,859
Other non-current assets:
Security deposits	10,000	10,000
Research and development supplies	2,532,226	2,347,488
Intellectual property, net	790,466	773,478
Total other assets	3,332,692	3,130,966
Total assets	12,564,591	10,670,592
Current liabilities:
Accounts payables	2,152,210	1,397,610
Other current liabilities	1,655,701	1,856,598
Total current liabilities	3,807,911	3,254,208
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2024, and December 31, 2023, respectively	0	0
Common stock $0.001 par value: 200,000,000 shares authorized; 1,922,586 and 1,485,902 shares issued and outstanding at March 31, 2024, and December 31, 2023, respectively	1,923	1,486
Additional paid-in capital	148,411,906	141,103,178
Accumulated deficit	(139,657,149)	(133,688,280)
Total stockholders’ equity	8,756,680	7,416,384
Total liabilities and stockholders’ equity	$ 12,564,591	$ 10,670,592

About Genprex Inc

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

CEO	Mr. John Rodney Varner
WEBSITE	genprex.com
INDUSTRY	Biotechnology
EMPLOYEES	30

Genprex Inc Frequently Asked Questions

What is the ticker symbol for Genprex Inc? What does GNPX stand for in stocks?

GNPX is the stock ticker symbol of Genprex Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Genprex Inc (GNPX)?

As of Fri May 17 2024, market cap of Genprex Inc is 5.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GNPX stock?

You can check GNPX's fair value in chart for subscribers.

What is the fair value of GNPX stock?

You can check GNPX's fair value in chart for subscribers. The fair value of Genprex Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Genprex Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GNPX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Genprex Inc a good stock to buy?

The fair value guage provides a quick view whether GNPX is over valued or under valued. Whether Genprex Inc is cheap or expensive depends on the assumptions which impact Genprex Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GNPX.